ANGPTL3

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

Retrieved on: 
Wednesday, June 30, 2021
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical trials, ANGPTL3, Dyslipidemia, Low-density lipoprotein, Branches of biology, Health, Chemistry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROANG3-2001, a Phase 2b clinical study of ARO-ANG3, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with mixed dyslipidemia.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROANG3-2001, a Phase 2b clinical study of ARO-ANG3, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with mixed dyslipidemia.
  • Javier San Martin, M.D., chief medical officer at Arrowhead, said: By inhibiting ANGPTL3, Arrowheads investigational ARO-ANG3 is designed to reduce triglycerides and LDL cholesterol in patients with mixed dyslipidemia.
  • The Phase 2b AROANG3-2001 clinical study will evaluate safety and efficacy, and identify an optimal dose and dosing regimen of ARO-ANG3 to be assessed in future late-stage clinical studies.
  • AROANG3-2001 ( NCT04832971 ) is a double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of investigational ARO-ANG3 in adults with mixed dyslipidemia.

Verve Therapeutics to Present Preclinical Data from Gene Editing Programs for the Treatment of Atherosclerotic Cardiovascular Disease at ASGCT

Retrieved on: 
Tuesday, May 11, 2021
Health, Genetics, Other Health, Pharmaceutical, Cardiology, Biotechnology, Lipids, Metabolic disorders, Medical specialties, Lipid metabolism disorders, Sterols, PCSK9, Familial hypercholesterolemia, Cardiovascular diseases, Low-density lipoprotein, ANGPTL3, Hypercholesterolemia, Cholesterol

b'Verve Therapeutics , a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the presentation of additional preclinical data from the company\xe2\x80\x99s gene editing programs for the treatment of atherosclerotic cardiovascular disease (ASCVD), the most common form of cardiovascular disease, at the American Society of Gene and Cell Therapy (ASGCT) 24th Virtual Annual Meeting.

Key Points: 
  • b'Verve Therapeutics , a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the presentation of additional preclinical data from the company\xe2\x80\x99s gene editing programs for the treatment of atherosclerotic cardiovascular disease (ASCVD), the most common form of cardiovascular disease, at the American Society of Gene and Cell Therapy (ASGCT) 24th Virtual Annual Meeting.
  • In a preclinical proof-of-concept study with an ANGPTL3-gene editor administered as a single dose to NHPs, Verve observed a 95% average reduction of blood ANGPTL3 protein levels.
  • The company\xe2\x80\x99s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease.
  • VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020

Retrieved on: 
Monday, August 31, 2020
Technology, Infectious diseases, Genetics, Clinical trials, Nanotechnology, Cardiology, Biotechnology, Pharmaceutical, Health, Oncology, Branches of biology, RNA, Apolipoprotein C3, Apolipoproteins, Gene expression, RNA interference, ANGPTL3, European Society of Cardiology, Molecular biology, Aro, Biology

The data were presented in back-to-back oral presentations at the European Society of Cardiology (ESC) Congress 2020.

Key Points: 
  • The data were presented in back-to-back oral presentations at the European Society of Cardiology (ESC) Congress 2020.
  • Javier San Martin, M.D., chief medical officer at Arrowhead, said: These positive results from the healthy volunteer, repeat-dose portion of the Phase 1/2 clinical studies of our cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, strongly support our plans to rapidly advance both drug candidates into later stage development.
  • These are precisely the traits we were looking for and further support our belief that RNAi is the optimal mechanism to inhibit APOC3 and ANGPTL3.
  • We also look forward to presenting additional data from studies in various patient populations at the National Lipid Association and American Heart Association meetings later this year.

Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3

Retrieved on: 
Wednesday, February 5, 2020
Research, Technology, Genetics, Clinical trials, Nanotechnology, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Apolipoproteins, Apolipoprotein C3, ANGPTL3, Aro, Tolerability

We achieved high levels of APOC3 and ANGPTL3 protein knockdown, which led to impressive reductions in triglycerides and other lipid parameters.

Key Points: 
  • We achieved high levels of APOC3 and ANGPTL3 protein knockdown, which led to impressive reductions in triglycerides and other lipid parameters.
  • From a safety and tolerability perspective, both ARO-ANG3 and ARO-APOC3 data continue to look similar to our other TRiM candidates.
  • This high level of pharmacologic activity with good safety and tolerability to date is precisely what we were hoping for.
  • We look forward to further investigating the potential for ARO-APOC3 and ARO-ANG3 to provide clinical benefits in patients.

Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019

Retrieved on: 
Monday, November 18, 2019
Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Cardiology, Apolipoprotein C3, Apolipoproteins, ANGPTL3, Triglyceride

The data were presented in two late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2019, in Philadelphia.

Key Points: 
  • The data were presented in two late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2019, in Philadelphia.
  • In particular, the knockdown in APOC3 and ANGPTL3 proteins and the resulting reductions in triglycerides and various lipid parameters strongly support our plan to initiate Phase 3 studies in 2020.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
  • We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Ionis provides third quarter financial results and improved 2019 guidance

Retrieved on: 
Wednesday, November 6, 2019
Car classifications, Cars, Ionis, ANGPTL3, Range Rover Evoque, American Association for the Study of Liver Diseases, Transthyretin, Liver, Off-road vehicles

Based on these strong results, we are substantially increasing our 2019 revenue, operating income and net income guidance.

Key Points: 
  • Based on these strong results, we are substantially increasing our 2019 revenue, operating income and net income guidance.
  • Ionis and GSK plan to report data from the HBV clinical program at the AASLD Liver Meeting in November 2019.
  • Ionis and Akcea plan to initiate the Phase 3 program for AKCEA-TTR-LRx in the fourth quarter of 2019.
  • Akcea and Ionis plan to report top line results from Phase 2 studies of AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx in early 2020.